Investor Presentation First Nine Months of 2022
24.
Investor presentation First nine months of 2022
Sales growth of 16%, driven by both NAO and IO with 22% and
11% sales growth respectively
DKK
billion
Novo NordiskⓇ
Historic and reported sales by geography
Reported sales and growth breakdown
for the first nine months of 2022
Regions
Sales
(mDKK)
Growth
Share of
growth
111.7
140.8
128.9
International Operations
64,415
11%
38%
13%
EMEA
32,722
13%
23%
14%
15%
10%
11%
10%
Region China
12,845
-5%
-4%
26%
27%
25%
ROW
18,848
22%
19%
North America Operations
64,447
22%
62%
Hereof USA
59,888
21%
55%
52%
48%
50%
Total sales
128,862
16%
100%
2017
2021
North America
EMEA
9M 2022
Region China
ROW
Source: Quarterly company announcement
IO: International Operations; NAO: North American Operations; EMEA: Europe, Middle East, and Africa; Row: Rest of World; Region China covers mainland China, Hong Kong and Taiwan; 9M: 9 months.
Note: Numbers may not add up to 100% due to rounding; Growth at Constant exchange rates; Sales numbers are reported in Danish kronerView entire presentation